Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer

Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study

(2021) Fiona Blackhall et al.   Journal of Thoracic Oncology

A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer

(2021) Jyoti Malhotra et al.   Journal of Thoracic Oncology

Unlocking the potential of antibody–drug conjugates for cancer therapy

(2021) Joshua Z. Drago et al.   Nature Reviews Clinical Oncology

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors

(2021) Kimio Yonesaka   Cancers

OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study

(2021) A. Spira et al.   Journal of Thoracic Oncology

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

(2021) Melissa L. Johnson et al.   Journal of Thoracic Oncology

OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01

(2021) K. Nakagawa et al.   Journal of Thoracic Oncology

Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

(2021) Aleksandr V. Yurkovetskiy et al.   MOLECULAR CANCER THERAPEUTICS

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

(2021) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

(2021) A. Bardia et al.   ANNALS OF ONCOLOGY

A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.

(2021) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

(2021) Bob T. Li et al.   NEW ENGLAND JOURNAL OF MEDICINE

OA15.04 Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer

(2021) D.R. Camidge et al.   Journal of Thoracic Oncology

Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).

(2020) Anas Gazzah et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.

(2020) Egbert F. Smit et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

(2020) Kohei Shitara et al.   NEW ENGLAND JOURNAL OF MEDICINE

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

(2020) Bob T. Li et al.   Cancer Discovery

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

(2020) Caicun Zhou et al.   JOURNAL OF CLINICAL ONCOLOGY

LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions

(2020) S.V. Liu et al.   ANNALS OF ONCOLOGY

CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration

(2020) Xinwen Zhang et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

(2019) Yuuri Hashimoto et al.   CLINICAL CANCER RESEARCH

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients

(2019) David E. Gerber et al.   CLINICAL CANCER RESEARCH

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study

(2019) Daniel Morgensztern et al.   CLINICAL CANCER RESEARCH

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

(2019) Jacqulyne P. Robichaux et al.   CANCER CELL

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

(2019) Jame Abraham et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

(2018) Bob T. Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

(2018) John D. Hainsworth et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer

(2018) Katsuyuki Hotta et al.   Journal of Thoracic Oncology

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).

(2018) Melissa Lynne Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

1383PDAn open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

(2018) R Camidge et al.   ANNALS OF ONCOLOGY

1491PA phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial

(2018) I Kinoshita et al.   ANNALS OF ONCOLOGY

Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies

(2018) Hao Xie et al.   Journal of Thoracic Oncology

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

(2017) Rebecca Suk Heist et al.   JOURNAL OF CLINICAL ONCOLOGY

ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET –Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence

(2016) Jieyi Wang et al.   CLINICAL CANCER RESEARCH

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

(2015) M. G. Kris et al.   ANNALS OF ONCOLOGY

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

(2015) Jacques De Grève et al.   LUNG CANCER

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

(2015) Laura R. Saunders et al.   Science Translational Medicine

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

(2015) P. K. Paik et al.   Cancer Discovery

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

(2015) G. M. Frampton et al.   Cancer Discovery

The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

(2012) H. K. Erickson et al.   MOLECULAR CANCER THERAPEUTICS